Results 71 to 80 of about 157,049 (314)
Adjuvants for Leishmania vaccines: From Models to Clinical Application
Frontiers in Immunology, 2012 Two million new cases of leishmaniasis occur every year, with the cutaneous leishmaniasis (CL) presentation accounting for approximately two-thirds of all cases.
Vanitha S. Raman +4 more
doaj +1 more source
Cognitive and Patient‐Reported Outcome Measures in LGI‐1‐IgG Autoimmune Encephalitis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Clinical outcome measures for autoimmune encephalitis (AE) are not yet well defined. Cognitive outcome measures (CogOs) and patient‐reported outcomes (PROs) may capture the symptoms of AE, beyond clinician‐reported outcomes (ClinROs) (the Modified Rankin Scale [mRS] and Clinical Assessment Scale in Autoimmune Encephalitis [CASE ...
Tatchaporn Ongphichetmetha +8 more
wiley +1 more source
Cancer, 1978 In this brief presentation, an attempt was made to illustrate why it is not possible to carry over chemotherapeutic trial results from one animal cancer to another or one human cancer to another without corrections for differences in (a) staging, (b) dose response, and (c) tumor regrowth rates.
openaire +2 more sources
BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach +11 more
wiley +1 more source
Журнал микробиологии, эпидемиологии и иммунобиологии, 2015 Aim. Direct immunogenicity comparison of adjuvants from various sources and with different mechanisms of action for inactivated influenza vaccines. Materials and methods.
M. I Chernikova +2 more
doaj
Frontiers in Immunology, 2018 The induction and modulation of the immune response to vaccination can be rationally designed by combining different vaccine formulations for priming and boosting.
Annalisa Ciabattini +10 more
doaj +1 more source
The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To quantify how often anti‐seizure medications (ASMs) appear ineffective yet provide benefit when considering seizure frequency (SF) variability. Methods We used the CHOCOLATES seizure diary simulator to generate 100,000 patient seizure diaries that reflect natural SF variation in a heterogeneous population.
Christopher N. Henry +1 more
wiley +1 more source
Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines
VaccinesBackground: Aluminum adjuvants, renowned for their safety and efficacy, act as excellent adsorbents and vaccine immunogen enhancers, significantly contributing to innate, endogenous, and humoral immunity.
Jingyang Lan +4 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The Apolipoprotein (APOE) ε4 allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD); however, many ε4 carriers remain cognitively intact into old age. Leveraging plasma neuron‐derived extracellular vesicles (NDEVs), we sought to identify biomarkers of cognitive resilience and their interplay with APOE ...
Apostolos Manolopoulos +17 more
wiley +1 more source
Progress and prospect of polysaccharides as adjuvants in vaccine development
VirulenceVaccines are an effective approach to confer immunity against infectious diseases. Modern subunit vaccines offer more precise target and safe protection compared to traditional whole-pathogen vaccines.
Xinlong Liang +6 more
doaj +1 more source